Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.